Industry Missing A Public Health Opening With DTC Ads, FDA’s Hamburg Says
The messages conveyed through pharmaceutical direct-to-consumer advertising, and FDA’s role in regulating such promotions, are ripe for re-examination, Commissioner Margaret Hamburg said July 25.
You may also be interested in...
Certain drug classes will be required to submit certain types of ads, according to Tom Abrams, director of CDER’s recently elevated Office of Prescription Drug Promotion, but specifics will await the guidance itself.
A planned study will examine the impact of including descriptions of the disease that go beyond a product's labeled claims.
Industry should be prepared for the fight over user fees for direct-to-consumer advertising to be revived during the fifth round of reauthorization of the Prescription Drug User Fee Act